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Introduction: Neutrophil gelatinase-associated lipocalin (NGAL), cystatin C (Cys-C), and soluble triggering receptor
expressed on myeloid cells-1 (sTREM-1) are novel diagnostic biomarkers of acute kidney injury (AKI). We aimed to
determine the diagnostic properties of these biomarkers for detecting AKI in critically ill patients with sepsis.
Methods: We divided 112 patients with sepsis into non-AKI sepsis (n = 57) and AKI sepsis (n = 55) groups. Plasma
and urine specimens were collected on admission and every 24 hours until 72 hours and tested for NGAL, Cys-C,
and TREM-1 concentrations. Their levels were compared on admission, at diagnosis, and 24 hours before diagnosis.
Results: Both plasma and urine NGAL, Cys-C, and sTREM-1 were significantly associated with AKI development in
patients with sepsis, even after adjustment for confounders by using generalized estimating equations. Compared with
the non-AKI sepsis group, the sepsis AKI group exhibited markedly higher levels of these biomarkers at diagnosis and
24 hours before AKI diagnosis (P <0.01). The diagnostic and predictive values of plasma and urine NGAL were good,
and those of plasma and urine Cys-C and sTREM-1 were fair.
Conclusion: Plasma and urine NGAL, Cys-C, and sTREM-1 can be used as diagnostic and predictive biomarkers for AKI
in critically ill patients with sepsis.Introduction
Sepsis is well known as a life-threatening syndrome that de-
velops as a result of systemic inflammatory response to in-
fection; it remains the leading cause of death and has a 30%
to 40% mortality rate in the intensive care unit (ICU) [1,2].
Acute kidney injury (AKI) is one of the leading causes of
sepsis-related death in critically ill patients, and 50% of all
cases of AKI are considered to be associated with sepsis
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unless otherwise stated.leading to AKI in patients with sepsis remain elusive, and
diagnostic tools that can detect AKI at an early stage are
lacking, and this may account for the very high morbidity
and mortality rates of sepsis-associated AKI. Currently, the
diagnosis of AKI is based mainly on an increase in the
serum creatinine (SCr) level, which indicates loss of excre-
tory renal function according to the Risk, Injury, Failure,
Loss, and End-stage Kidney disease (RIFLE) [5], Acute Kid-
ney Injury Network (AKIN) [6], and Kidney Disease:
Improving Global Outcomes (KDIGO) criteria [7]. How-
ever, the SCr level does not accurately reflect the glomeru-
lar filtration rate (GFR) in patients with sepsis, as GFR is
regulated by tubular creatinine secretion and non-renal fac-
tors such as liver function, muscle mass, and non-renal
gastrointestinal elimination [8]. SCr is also recognized as
a late marker of kidney injury [9,10]. For these reasons, its is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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early diagnosis of sepsis-associated AKI.
Numerous potential markers for the early diagnosis of
AKI have been under study in the last decade. Among
these biomarkers, neutrophil gelatinase-associated lipocalin
(NGAL), cystatin C (Cys-C), and soluble triggering recep-
tor expressed on myeloid cells-1 (sTREM-1) have received
the most attention. Although several studies have already
focused on the performance of these biomarkers for diag-
nosing AKI in patients with or without sepsis [11-18], the
diagnostic properties of these biomarkers remain a matter
of debate because of the complexity of clinical conditions
and pathological processes. NGAL, a 25-kDa protein that
covalently binds to gelatinase from neutrophils, is rapidly
released by activated neutrophils in response to ischemic
or toxic damage [11,19]. According to experimental and
clinical studies, NGAL is one of the most promising early
biomarkers of AKI [11,18]. Cys-C, another functional
biomarker, has been found to be superior to SCr as a
marker of renal function [20]. However, its diagnostic
value is not clear. Most research demonstrates that
Cys-C functions well as a predictor of AKI [12,14,21], but a
few studies have shown that it is a poor predictor [15,22].
The expression of TREM, a glycoprotein of the immuno-
globulin superfamily, in neutrophils and monocytes is
upregulated in the presence of infection [23,24]. Its
role is to amplify the innate inflammatory response
and sepsis mediated by the engagement of Toll-like
receptors and nucleotide-binding oligomerization domain
(NOD)-like receptors [25-27]. sTREM-1, the soluble form
of TREM-1, is extensively released into peripheral circula-
tion upon upregulation of the expression of TREM-1
[25,26]. Su et al. [16] have reported that this 27-kDa
protein can be excreted by the kidney provided that
kidney injury exists. An increasing number of studies
indicate that patients with sepsis have increased
sTREM-1 levels in body fluid samples, which are closely
related to the severity of infection and are predictive
markers of prognosis [28].
Despite such extensive research into these markers, the
diagnostic properties of NGAL, Cys-C, and sTREM-1 with
regard to AKI occurrence in patients with sepsis need to
be clarified. This study was designed to determine the
diagnostic and predictive value of these biomarkers for
sepsis-associated AKI in a general ICU population.
Methods
Study population
This prospective observational study was conducted at the
general ICU of the First Peoples’ Hospital of Chenzhou,
Hunan Province, China. The protocol was approved by
the Ethics Committee (project 2012033-003) of the First
Peoples’ Hospital of Chenzhou. Patients or their family
members were fully informed of the study details andsigned the informed consent forms of their own accord.
All of the consecutive eligible patients were selected from
among inpatients who were hospitalized between March
2012 and March 2014. One hundred twelve patients with
sepsis were included in the study and were divided into
two groups: a non-AKI sepsis group (n = 57) and an AKI
sepsis group (n = 55). The AKI sepsis group comprised
sepsis patients who developed AKI during the first week.
The patients were screened daily for AKI occurrence for
up to days 7.Inclusion and exclusion criteria
Consecutive adult (at least 18 years old) sepsis patients
admitted to the ICU were assessed for inclusion. The
following patients were excluded: (1) those who did not
give their consent or who declined treatment during the
period of observation; (2) those who were exposed to the
presence of radiocontrast agents or nephrotoxin drugs 5
days prior to admission; (3) those with pre-existing AKI
(known in any stage of AKI prior to admission); (4) those
with chronic kidney disease (CKD), defined according to
the definition of the National Kidney Foundation as kidney
damage or GFR of less than 60 mL/min per 1.73 m2 for at
least 3 months, irrespective of the cause [29]; (5) those who
had undergone renal transplant; (6) those who required
renal replacement therapy (RRT); (7) those with anuria; (8)
those with cancer; (9) those who had participated in other
studies; (10) those who had contracted AIDS; and (11)
those who had undergone high-dose steroid treatment.Definitions
According to the diagnostic criteria of the 2001 Inter-
national Sepsis Definition Conference [30], sepsis is a
systemic, deleterious host response to infection leading
to systemic inflammatory response syndrome, which
is characterized by two or more of the following condi-
tions: hypothermia or fever (body temperature of less than
36°C or more than 38.5°C, respectively), tachycardia
(>90 beats per minute), tachypnea (>20 breaths per
minute or partial pressure of arterial carbon dioxide
(PaCO2) of less than 32 mm Hg during mechanical
ventilation), leukocytosis (>12,000/mm3), leukopenia
(<4,000/mm3), and an increase in the number of imma-
ture band forms (>10%).
According to the 2012 KDIGO criteria [7], which are
based on the RIFLE/AKIN definitions, we used the
urine output and SCr components as indicates of
AKI. The AKI is characterized by a 48-hour absolute
increase in SCr of at least 26.4μmol/L, and an in-
crease of at least 50% from baseline that is known or
presumed to have occurred within the prior 7 days,
and a decline in urine output to not more than
0.5mL/kg per hour for at least 6 hours.
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When the patients were admitted to the ICU, data on the
baseline characteristics, including age, gender, etiological
factors, and underlying diseases, were collected. SCr
levels were obtained on admission and every 12 hours
(9 a.m. and p.m. ± 1 hour), and urine output was recorded
every hour for diagnosing AKI. To determine the severity
of inflammation, the white blood cell (WBC) count and
the level of C-reactive protein (CRP) and procalcitonin
(PCT) were determined. Other physiological and clinical
information was collected and scored by using the
Sequential Organ Failure Assessment (SOFA) score
and Acute Physiology and Chronic Health Evaluation II
(APACHE II) score.
Sample processing and measurement
Blood and urine samples were obtained on admission
and every 24 hours up to 72 hours for measuring the
NGAL, Cys-C, and sTREM-1 levels. Blood was centrifuged
at 3,000 revolutions per minute (rpm) for 15 minutes, and
urine was centrifuged at 2,000 rpm for 5 minutes. The
supernatants were transferred to Eppendorf tubes and
stored at −80°C. All of the specimens were renumbered
before the experiment. The plasma NGAL level was
determined by using a Triage NGAL Assay (Alere
Inc., San Diego, CA, USA), and the measurable range
was 15 to 1,300 ng/mL. The urine NGAL level was
analyzed by using a NORMAN-2 scattering turbidimetry
analyzer with an NGAL Assay (Norman Inc., Nanjing,
China), and the measurable range was 0 to 4,000 ng/mL.
The Cys-C level was measured by using an automated
chemistry analyzer (Hitachi 7600 Clinical Analyzer;
Hitachi, Tokyo, Japan) with a latex immunoturbidimetry
assay. The level of sTREM-1 was determined by using a
double-antibody sandwich enzyme-linked immunosorbent
assay (ELISA) (R&D Systems Inc., Minneapolis, MN,
USA) with a measurable range of 0 to 4,000 pg/mL. ELISA
was performed in duplicate, and other assays were
performed in strict accordance with the instructions of
the manufacturers. Laboratory investigators were blinded
to the clinical information throughout the study.
Statistical analysis
Results for continuous variables with normal distribu-
tion, including age, mean arterial pressure (MAP),
APACHE II and SOFA scores, and SCr, are presented
as mean ± standard deviation. The Student’s t test
was used to compare means between the two groups.
Results for continuous variables that were not normally dis-
tributed, including WBC counts, CRP, PCT, urine NGAL,
plasma NGAL, plasma sTREM-1, urine sTREM-1, plasma
Cys-C, and urine Cys-C, are presented as the median values
(25th and 75th percentiles) and were compared by using
the Mann-Whitney U test. Results for qualitative variableswere expressed as number (percentage) and compared
between groups by using the chi-square test or Fisher’s
exact test. Survival rates were calculated by using the
Kaplan-Meier method, and between-group differences
were assessed by using the log-rank test. Odds ratios and
the corresponding confidence intervals (CIs) for models of
these biomarkers in plasma and urine with the risk of AKI
occurrence in sepsis were analyzed by using generalized
estimating equations (GEEs). The variables were com-
bined to create three models. In model 1, no moderator
variables were adjusted; in model 2, SCr was used as the
moderator variable; and in model 3, MAP, APACHE II
scores, SOFA scores, and PCT were adjusted in addition
to SCr. Receiver operating characteristic (ROC) analysis
was used to explore the ability of these biomarkers to pre-
dict AKI occurrence in patients with sepsis at diagnosis and
24 hours before diagnosis. Areas under the receiver
operating characteristic curves (AUROCs) were used to
evaluate how well the model could distinguish AKI patients
with sepsis from non-AKI patients with sepsis. Statistical
analyses were conducted by IBM SPSS 19.0 (SPSS, Chicago,
IL, USA), and a two-tailed P value of less than 0.05 was
considered to indicate statistical significance.
Results
Patient characteristics
In total, 251 consecutive patients were screened. Of these,
109 patients were later excluded according to the exclusion
criterion. Of the remaining 142 patients, 30 were excluded
for various reasons during the observation period (Figure 1).
Finally, 112 were included: 57 without AKI and 55 with
AKI. The number of deaths increased with time during the
first week in the non-AKI sepsis group and in the AKI sep-
sis group. Survival analysis showed that the AKI sepsis
group had a poor prognosis (hazard ratio = 0.43, 95% CI
0.202 to 0.924, χ2 = 4.681, P = 0.031) (Figure 2).
Fifty-five patients with sepsis (49.1%) developed AKI
based on the KDIGO criteria during the 7-day observation
period. The number of sepsis-associated AKI patients
increased with time (Figure 2B). The serum PCT level and
disease severity scores, including the APACHE II and
SOFA scores, were significantly higher in the AKI patients
than in the non-AKI patients (P <0.01 for all). Both
the plasma and urine NGAL, Cys-C, and sTREM-1
levels (P <0.01 for all) were significantly different between
the two groups. There was no significant difference in age,
gender, WBC count, serum CRP, SCr, MAP, mechanical
ventilation, etiological factors, or underlying diseases
(P >0.05 for all) (Table 1).
Risk for acute kidney injury occurrence in patients with
sepsis
On the basis of the results of the univariate analysis, four
variables (P <0.1) were selected for multivariate analysis.
Figure 1 Flow chart depicting the selection process. AIS, acquired
immunodeficiency syndrome; AKI, acute kidney injury; CKD, chronic
kidney disease; RRT, renal replacement therapy.
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sion with GEE are shown in Table 2. The biomarkers
analyzed showed significant associations with the end-
point (AKI occurrence) in patients with sepsis (P <0.001)
based on KDIGO criteria. The significance was appar-
ent even after adjustment for possible confounders in
model 2 (SCr) and model 3 (MAP, APACHE II scores,
SOFA scores, and PCT in addition to SCr).Figure 2 Survival curves and proportion of septic patients who developed
AKI. The septic patients who developed AKI trended to a poor prognosis (P
septic patients who developed AKI. The number of sepsis-associated AKI paDynamic changes in both plasma and urine NGAL,
Cys-C, and sTREM-1 levels
The differences in the levels of these biomarkers at the
four different time points at which they were measured
(on admission and 24, 48, and 72 hours after admission)
were significant (P <0.01 for all), and the sepsis-related
AKI patients had all-time higher values. In addition,
dynamic changes in both plasma and urine NGAL,
Cys-C, and sTREM-1 levels on admission and 24, 48,
and 72 hours after admission in the septic patients
without AKI are summarized and shown in Figure 3.
Similarly, the time courses of these markers within 72
hours prior to the endpoint (AKI occurrence) and 48
hours after AKI occurrence in AKI septic patients are
shown in Figure 3.
Diagnostic value of the NGAL, Cys-C, and sTREM-1 levels
for AKI occurrence in patients with sepsis
To examine the diagnostic values of plasma and urine
NGAL, Cys-C, and sTREM-1 for sepsis-associated AKI,
we used the data of 57 non-AKI sepsis patients on
admission and 49 AKI sepsis patients at the same
time point if AKI diagnosis was based on the SCr
values at 9 a.m. or at the next time point if it was
based on either urine output or the SCr values at 9
p.m. The data for six AKI sepsis patients were not
used since five patients developed AKI after 96 hours
and one patient died after AKI diagnosis but before
the next test. The NGAL (Figure 4A and B), Cys-C
(Figure 4C and D), and sTREM-1 (Figure 4E and F)
levels in both the plasma and urine samples of AKI
sepsis patients were found to be significantly ele-
vated when compared with those of the non-AKI
sepsis patients (P <0.01 for all). Figure 5 shows the
AUROCs and the 95% CIs for NGAL, Cys-C, and
sTREM-1 for AKI occurrence in patients with sepsis.
The results indicate that plasma and urine NGAL
(AUROC 0.823, 95% CI 0.730 to 0.916 and AUROCacute kidney injury (AKI). (A) Survival in sepsis patients with or without
= 0.031). The log-rank test for trend was used. (B) The proportion of
tients increased with time during the observation.
Table 1 Clinical and biological data on admission
Characteristics Non-AKI sepsis AKI sepsis P value
(n = 57) (n = 55)
Age, years 51.0 ± 15.6 49.8 ± 15.4 0.664
Gender, n (%)
Male 35 (61.4) 27 (49.1) 0.190
Female 22 (38.6) 28 (50.9)
Etiological factors, n (%)
Pulmonary infection 17 (29.8) 16 (29.1) 0.549
Abdominal infection 14 (24.6) 17 (30.1) 0.295
Urinary tract infection 9 (15.8) 9 (16.4) 0.569
Trauma-related
infection
8 (14.0) 3 (5.5) 0.113
Bacteremia 3 (5.3) 3 (5.5) 0.635
Catheter-related
infections
3 (5.3) 3 (5.5) 0.635
Others 3 (5.3) 2 (5.5) 0.525
Underlying diseases, n (%)
Hypertension 35 (61.4) 31 (56.4) 0.406
Diabetes 30 (52.6) 24 (43.6) 0.170
COPD 16 (28.1) 16 (28.1) 0.535
Coronary heart disease 16 (28.1) 15 (27.3) 0.547
Nervous system
disease
17 (29.8) 11 (20.0) 0.382
WBC count, ×109/L 15.0 (12.5, 17.8) 16.0 (12.0, 21.0) 0.610
MAP, mm Hg 70.4 ± 14.4 65.9 ± 12.7 0.085
Serum CRP, mg/dL 54.2 (32.2, 60.5) 54.0 (43.3, 67.8) 0.131
Serum PCT, ng/mL 7.0 (3.2, 23.4) 22.1 (6.5, 56.0) 0.002
SCr, μmol/L 79.5 ± 27.9 77.4 ± 33.3 0.721
APACHE II score 15.1 ± 3.4 17.2 ± 4.3 0.004
SOFA score 8.0 ± 2.1 9.4 ± 2.9 0.005
Mechanical ventilation,
n (%)
22 (36.7) 28 (53.8) 0.131
Plasma NGAL, ng/mL 123.0 (98.0, 170.5) 165.0 (124.0, 343.0) <0.001
Urine NGAL, ng/mL 54.0 (43.1, 65.0) 187.0 (76.0, 265.8) <0.001
Plasma Cys-C, mg/L 1.09 (0.98, 1.22) 1.23 (1.08, 1.45) 0.001
Urine Cys-C, mg/L 0.12 (0.09, 0.13) 0.13 (0.10, 0.32) 0.002
Plasma sTREM-1, pg/mL 98.0 (86.0, 122.15) 132.0 (98.7, 155.0) <0.001
Urine sTREM-1, pg/mL 43.0 (23.7, 54.9) 54.0 (34.65, 65.0) 0.012
Quantitative data with normal distribution are presented as mean ± standard
deviation. Quantitative data with non-normal distribution are presented as
median (25th and 75th percentiles). Qualitative data are presented as number
(percentage). AKI, acute kidney injury; APACHE II, Acute Physiology and
Chronic Health Evaluation II; COPD, chronic obstructive pulmonary disease;
CRP, C-reactive protein; Cys-C, cystatin C; MAP, mean arterial pressure; NGAL,
neutrophil gelatinase-associated lipocalin; PCT, procalcitonin; SCr, serum
creatinine; SOFA, Sequential Organ Failure Assessment; sTREM-1, soluble
triggering receptor expressed on myeloid cells-1; WBC, white blood cell.
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well for the diagnosis of AKI occurrence and that plasma
and urine Cys-C (AUROC 0.795, 95% CI 0.704 to 0.885and AUROC 0.772, 95% CI 0.682 to 0.862, respectively)
and sTREM-1 (AUROC 0.794, 95% CI 0.708 to 0.880 and
AUROC 0.707, 95% CI 0.610 to 0.805, respectively)
performed fairly well.
Predictive values of the NGAL, Cys-C, and sTREM-1 levels
for AKI occurrence 24 hours before its diagnosis in
patients with sepsis
To assess the predictive values of plasma and urine
NGAL, Cys-C, and sTREM-1 for AKI occurrence 24
hours before its diagnosis in patients with sepsis, we
used the data of 57 non-AKI sepsis cases on admission
and 34 AKI sepsis patients at the last time point before
AKI occurrence. The data for 21 patients were not used,
because 16 of them in the AKI group developed AKI
within the first 24 hours and five developed AKI after 96
hours. We found that 24 hours before AKI occurrence,
the AKI sepsis patients had significantly increased
plasma and urine NGAL (Figure 4A and B), Cys-C
(Figure 4C and D), and sTREM-1 (Figure 4E and F)
levels (P <0.01 for all) compared with the non-AKI
sepsis patients. Figure 5 shows the AUROCs and cor-
responding 95% CIs for NGAL, Cys-C, and sTREM-1
for AKI prediction at 24 hours before AKI diagnosis
in the patients with sepsis. The results indicate that plasma
and urine NGAL (AUROC 0.830, 95% CI 0.741 to 0.919
and AUROC 0.879, 95% CI 0.793 to 0.948, respectively)
were good indicators of AKI occurrence and that plasma
and urine Cys-C (AUROC 0.737, 95% CI 0.633 to 0.841
and AUROC 0.741, 95% CI 0.641 to 0.841, respectively)
and sTREM-1 (AUROC 0.746, 95% CI 0.646 to 0.846 and
AUROC 0.778, 95% CI 0.687 to 0.870, respectively) also
performed fairly well.
Discussion
In this investigation, we have shown that the plasma
and urine NGAL, Cys-C, and sTREM-1 can be used
for diagnosing and predicting AKI occurrence in patients
with sepsis. Sepsis-associated AKI is associated with a
longer length of hospital stay and higher morbidity
and mortality rates in critically ill patients [3,16].
Timely diagnosis and effective interventions such as fluid
resuscitation, early antibiotic initiation, and restricted use
of contrast dye and nephrotoxic drugs at the early stage of
sepsis may help to significantly improve the clinical course
of the disease. The current diagnostic criteria for AKI,
including the RIFLE, AKIN, and KDIGO criteria, all rely
on an increase in the SCr level. However, there are some
problems associated with this marker in clinical practice.
For example, baseline SCr levels are not usually available in
the clinical setting. In addition, changes in SCr primarily
reflect functional changes in filtration capacity, which may
not be valid markers of renal injury. Although a number of
studies on new biomarkers for AKI occurrence have been
Table 2 Acute kidney injury risk indicated by these biomarkers in septic patients analyzed by using logistic regression
with generalized estimating equations
Variable Crude: model 1a Adjusted: model 2b Adjusted: model 3c
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Plasma NGAL 1.013 (1.010-1.015) <0.001 1.012 (1.009-1.014) <0.001 1.013 (1.010-1.022) <0.001
Urine NGAL 1.030 (1.014-1.047) <0.001 1.029 (1.014-1.045) <0.001 1.027 (1.011-1.044) 0.001
Plasma Cys-Cd 1.003 (1.002-1.004) 0.001 1.003 (1.002-1.003) 0.001 1.003 (1.002-1.003) <0,001
Urine Cys-Cd 1.010 (1.005-1.014) <0.001 1.024 (1.018-1.038) <0.001 1.022 (1.008-1.035) 0.001
Plasma sTREM-1 1.029 (1.021-1.037) <0.001 1.023(1.016-1.031) <0.001 1.028(1.018-1.037) <0.001
Urine sTREM-1 1.038(1.019-1/057 <0.001 1.033(1.016-1.050 <0.001 1.031(1.009-1.053) 0.005
aNot adjusted. bAdjusted for serum creatinine (SCr). cAdjusted for mean arterial pressure, Acute Physiology and Chronic Health Evaluation II scores, Sequential
Organ Failure Assessment scores, and procalcitonin in addition to SCr. dOdds ratio (ORs) represent the increase in risk per 0.001 mg/L increase in cystatin C
(Cys-C). CI, confidence interval; NGAL, neutrophil gelatinase-associated lipocalin; sTREM-1, soluble triggering receptor expressed on myeloid cells-1.
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universally accepted and used in clinical practice.
To evaluate the reliability of NGAL, Cys-C, and
sTREM-1 levels for early diagnosis of sepsis-associated
AKI, the plasma and urine levels were continuously
monitored in the present study. We found that both the
plasma and urine NGAL levels were good markers for
the diagnosis and prediction of AKI occurrence in
patients with sepsis. Recent studies have shown that
urine NGAL is a useful biomarker for diagnosing AKI in
patients with sepsis [13,21]; however, the diagnostic
value of plasma NGAL is under debate. On the one
hand, an increasing number of studies, including the
present one, indicate that plasma NGAL has good
diagnostic value for sepsis-associated AKI [17,31]. On
the other hand, Aydogdu et al. [21] demonstrated that
plasma NGAL is a poor predictor of AKI occurrence in
septic patients with an AUROC of 0.44, and a study
by Martensson et al. [13] showed that it was a poor
indicator (AUROC of 0.67) of AKI occurrence in the
12 hours following septic shock. These results can be
explained by the reabsorption of NGAL largely by
efficient megalin-dependent endocytosis [21]. In keeping
with this, Matsa et al. [18] reported that the diagnostic
accuracy of NGAL for AKI may be more precise if
patients with pre-existing kidney disease are excluded.
Therefore, our findings conclusively show the diagnostic
value of plasma NGAL for AKI occurrence in patients
with sepsis since we excluded patients with pre-existing
kidney disease.
Cys-C has been considered an early predictor of AKI
and an independent predictor of mortality [14,21,24].
In the present study, the AUROC results for both
plasma and urine Cys-C indicated that it could be
useful in discriminating septic patients with AKI from
those without AKI at diagnosis and 24 hours before
AKI diagnosis. This has been confirmed in a study by
Aydogdu et al. [21] which demonstrated that plasma
and urine Cys-C are good markers for the early diagnosisof sepsis-associated AKI (AUCs of 0.82 and 0.86, respect-
ively, and thresholds of 1.5 and 0.106 mg/L, respectively);
however, their study included patients who had cancer as
well as those undergoing steroid treatment and RRT.
However, a few studies in adults [12,32] as well as neonates
[22] showed that sepsis had no impact on the plasma or
urine levels of Cys-C. Therefore, the diagnostic value of
Cys-C for detecting AKI in patients with sepsis needs to be
confirmed by future studies with a larger sample.
TREM-1 has been identified as an important cell
surface molecule involved in sepsis. It is actively
expressed in response to infections, and upregulation
of its expression is accompanied by an increase in the
release of its soluble form (sTREM-1) [25]. Su et al.
[16] first reported that urine sTREM-1 was an excellent
predictor of AKI occurrence at 48 hours before diagnosis,
based on a cutoff point of 69.04 pg/mL (AUROC of
0.922, 95% CI 0.850 to 0.995), a sensitivity of 0.941,
and a specificity of 0.76. However, no data were available
24 hours before onset, because samples were collected
every other day. To the best of our knowledge, no study
has evaluated the diagnostic and predictive value of
plasma sTREM-1 for sepsis-associated AKI. Therefore,
the present study is the first to show the diagnostic and
predictive value of plasma sTREM-1 for AKI occurrence
(AUROCs of 0.794 and 0.746, respectively). We also found
that urine sTREM-1 was a fairly good predictor at the
time of diagnosis (AUROC of 0.707) and 24 hours before
diagnosis (AUROC of 0.778). The diagnostic and predictive
value of urine sTREM-1 in our study was lower than that
in the study by Su et al., probably because of the difference
in the study population and the use of a higher cutoff value
in their study.
Our study makes an important contribution to the
current body of studies on timely detection of AKI in
patients with sepsis as it provides more conclusive
evidence of the potential of these novel biomarkers
for diagnosing AKI in sepsis. It is conceivable that
the integration of these ideal markers into clinical
Figure 3 Time course of plasma and urine NGAL, Cys-C, and sTREM-1 levels in non-AKI septic patients (A, C, E) and AKI septic patients (B, D, F).
For non-AKI septic patients, the time course of these markers in the plasma and urine was explored since their ICU admission. For the AKI septic
patients, the time course was from 72 hours prior to AKI development to 48 hours after the endpoint. Data were presented as mean values and
95% confidence intervals. AKI, acute kidney injury; Cys-C, cystatin C; NGAL, neutrophil gelatinase-associated lipocalin; sTREM-1, soluble triggering
receptor expressed on myeloid cells-1.
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treatment, improve prognosis, and reduce hospitalization
cost. Recently, G1 cell cycle arrest biomarkers (insulin-like
growth factor-binding protein-7 and tissue inhibitor of
metalloproteinases-2), key molecules implicated in AKI,
have been identified and validated in independent
multicenter cohorts; it was shown that the two markers in
urine are superior to existing biomarkers [33]. It would be
interesting to explore these biomarkers in future studies.
Our study has several strengths. (1) As far as we are
aware, previous studies reported potential biomarkers for
the early diagnosis of sepsis-associated AKI in different
study populations and under non-uniform criteria. In thepresent study, we demonstrated the diagnostic and
predictive values of potential biomarkers under stan-
dardized conditions and strict exclusion criteria in the
general ICU. We ruled out potential factors that
could affect the accuracy of the results: for example,
patients with pre-existing AKI and CKD and those
who underwent renal transplant and were under RRT and
high-dose steroid treatment were excluded (Figure 1).
Although our study involved other interceptive subjects
with other conditions, including those with coronary heart
disease [34], diabetes [20], and urinary tract infections
[35], the proportion of these patients did not significantly
differ between the two groups (Table 1). (2) This is the
Figure 4 Comparison of the plasma NGAL (A), urine NGAL (B), serum Cys-C (C), urine Cys-C (D), plasma sTREM-1 (E), and urine sTREM-1
(F) levels at the time of AKI diagnosis and 24 hours before AKI diagnosis between the AKI sepsis group and the non-AKI sepsis group.
Sepsis-related AKI patients exhibit higher levels of these markers at diagnosis and 24 hours before AKI diagnosis. *P <0.01, compared with the non-AKI
sepsis group. AKI, acute kidney injury; Cys-C, cystatin C; NGAL, neutrophil gelatinase-associated lipocalin; sTREM-1, soluble triggering receptor expressed
on myeloid cells-1.
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tions to exclude patients undergoing RRT. Kiers et al. [36]
observed that Cys-C (13 kDa) concentrations in six septic
shock patients undergoing continuous RRT decreased
significantly following initiation of continuous veno-
venous hemofiltration within the first 24 hours (P = 0.04).
In the study by Mayeur et al. [37], 3 hours of intermittent
hemodialysis decreased the Cys-C concentrations by 30%.
This confirmed that the serum Cys-C concentrations are
altered in patients who undergo RRT. Our future studies
will investigate whether NGAL (25 kDa) and sTREM-1
(27 kDa) in the bloodstream could be attenuated by RRT
(hemofiltration or hematodialysis), as reported for Cys-C.
(3) Recently, NGAL and sTREM-1 have been suggested askey players in different cancers [38,39], but since patients
with cancer were excluded in our study, the findings for
AKI are still valid.
There are several limitations to this study. (1) This
was a single-center study, and the number of patients
analyzed was insufficient. The present findings need
to be validated in multicenter ICUs with larger cohorts.
(2) Previous studies have suggested that these markers
might be associated with the prognosis of sepsis-associated
AKI [16,18,21,32]. Our study did not analyze the associ-
ation between these biomarkers and the prognosis of the
disease, since the observation period was only 7 days. (3)
In line with most studies [13,15,16], we screened ‘day to
day’ for AKI occurrence, but the patients were not under
Figure 5 Diagnostic and predictive value of the NGAL Cys-C, and sTREM-1 levels for AKI at diagnosis (A) and 24 hours before diagnosis (B) in
patients with sepsis. Both plasma and urine NGAL performed well for diagnosing and predicting AKI in patients with sepsis, and both plasma
and urine Cys-C and sTREM-1 performed fairly well. Data are presented as AUROCs (95% CIs). AKI, acute kidney injure; AUROC, area under the receiver
operating characteristic curve; CI, confidence interval; Cys-C, cystatin C; NGAL, neutrophil gelatinase-associated lipocalin; sTREM-1, soluble triggering
receptor expressed on myeloid cells-1.
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diagnosis was defined as the first observation time point
after AKI occurrence, and the time point before that was
24 hours before the diagnosis. It is possible that a small
number of patients with sepsis had an abnormal GFR value
that was undetected by current criteria prior to admission
or that a time lag was present from admission until the first
sampling. (4) There was no non-septic AKI group or non-
septic non-AKI group for comparison in the present study.
It cannot be denied that sufficient comparison with these
control groups can increase the persuasive power of diag-
nostic properties. (5) We also did not exclude patients with
thyroid dysfunction, although there is no definitive evi-
dence that thyroid function affects the diagnostic accuracy
of these biomarkers in detecting AKI occurrence in critic-
ally ill patients [40].
Conclusions
Our study shows that the septic patients who develop AKI
have continuously elevated NGAL, Cys-C, and sTREM-1
concentrations in both the plasma and urine compared
with those without AKI from admission up to 72 hours
after admission. Moreover, these biomarkers showed good
validity for the diagnosis and prediction of AKI occurrence
in patients with sepsis. Owing to the limitations of our
observation, multicenter prospective studies are needed to
provide further proof for the clinical diagnostic and
predictive value of these potential biomarkers.
Key messages
 Sepsis-associated AKI patients show a continuous
increase in both plasma and urine NGAL, Cys-C,
and sTREM-1 levels up to 72 hours. Sepsis-associated AKI patients exhibit markedly
higher levels of plasma and urine NGAL, Cys-C,
and sTREM-1 levels at diagnosis and 24 hours
before AKI diagnosis.
 Both plasma and urine NGAL, Cys-C, and sTREM-1
showed a significant association with the development
of AKI in patients with sepsis, even after adjustment
for possible confounders.
 The diagnostic and predictive values of plasma and
urine NGAL were good, whereas those of plasma
and urine Cys-C and sTREM-1 were fair.Abbreviations
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